TMEM260

Across TCGA pan-cancer cohorts, TMEM260 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM260 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TMEM260 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TMEM260 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where TMEM260 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	1.000	0.942	.022	10	view →
LUAD	DFS	Median	II,III,IV	0.359	0.724	.027	9	view →
PDAC	DFS	Median	II,III,IV	0.578	0.991	.008	3	view →
HNSC	DFS	Median	III,IV	0.627	0.902	.010	2	view →
CCRCC	OS	Median	III,IV	0.863	0.578	.021	1	view →
GBM	OS	Median	All	0.996	0.827	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM260–LSCC (OS)

Open the LSCC breakdown →